Cancer Antigen 72-4 (CA 72-4)
| Product Name | Cancer Antigen 72-4 |
| Source | Human Metastatic Liver Carcinoma |
| Catalogue Number | 151-24 |
| Purity | > 90% (SDS-PAGE) |
| Form | Liquid |
| Activity | > 100 kU/mL |
| Formulation | Solution in phosphate buffered saline, pH 7.4 with sucrose and 0.05% sodium azide. |
| Pairing Information | Capture Ab: 151-22 - anti-Human CA 72-4 Monoclonal Antibody Detection Ab: 151-23 - anti-Human CA 72-4 Monoclonal Antibody Antigen: 151-24 - CA 72-4 from human metastatic liver |
| Storage | -20°C |
| Recertification | 2 years |
| Related Products | 151-25 - CA-125 antigen from human ascites fluid 151-53 - CA 15-3 antigen from human ascites fluid 151-10 - CEA antigen from human liver |
| Synonyms | CA 72-4, Cancer Antigen 72-4, Cancer Antigen Tag-72 |
| Molecular Weight | > 1,000,000 |
Lee Biosolutions is the leading producer and supplier of Cancer Antigen 72-4 (CA 72-4) for malignant diseases such as carcinomas of the pancreas, stomach, colon and ovaries.
Custom preparations, technical support, bulk quantities and aliquoting available, email Info@leebio.com for more details.
Elevated CA 72-4 levels in serum and plasma have been reported in various malignant diseases including carcinomas of pancreas, stomach, gallbladder, colon, ovaries, cervix and endometrium. The highest diagnostic sensitivities, according to current studies, are found for carcinomas of the gastrointestinal tract and ovaries.
Although some benign diseases such as rheumatic diseases or ovary cysts may also result in elevated levels of CA 72-4, clinical studies demonstrated diagnostic specificity of more than 95% for gastrointestinal and ovarian malignancies. There is a good correlation between CA 72-4 levels and tumor stage and size.
CA 72-4 is the marker of choice for the therapeutic monitoring and follow-up care of gastrointestinal cancer patients. Suitable second markers are CA 19-9 or CEA. It has been used as an independent marker for the therapeutic monitoring and follow-up care of ovarian cancer patients, in particular in CA 125 negative patients.
Lee Biosolutions, Inc
